AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00376558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Reinforcement Approach
Description: Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
Study NCT01228032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care team
Description: The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
Study NCT00912678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF (Cellcept) and Steroids
Description: Prograf was withdrawn completely after randomization, MMF and steroids were given.
Study NCT03787147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Google Cardboard
Description: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
Study NCT03787147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus
Description: Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
Study NCT03787147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
Study NCT03787147 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Hydrochloride
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
Study NCT03787147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
Study NCT03787147 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
Study NCT02956148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [18F]MNI-659
Description: The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
Study NCT03574363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.25 mg tablet
Description: Oral administration, QD, 84 days
Study NCT03574363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KBP-5074 0.25 mg tablet
Description: Oral administration, QD, 84 days
Study NCT03574363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.5 mg tablet
Description: Oral administration, QD, 84 days
Study NCT03574363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KBP-5074 0.5 mg tablet
Description: Oral administration, QD, 84 days
Study NCT03576651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1149
Description: Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
Study NCT03576651 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
Study NCT00035984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00035984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00035984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00035984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT04467255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative training
Description: 4 weeks aerobic treadmill training compared to endurance training with elastic thera band
Study NCT00912678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Prograf)
Description: After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
Study NCT02159612 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
Study NCT03405610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Toolkit for Optimal Recovery after Injury
Description: The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
Study NCT00003099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Daily for 14-28 days.
Study NCT00003099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Daily for 14-28 days.
Study NCT00003099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14-28 days
Study NCT02526901 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00706810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
Study NCT00706810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
Study NCT00723216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 20 mg twice a day
Study NCT00723216 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical prophylaxis
Study NCT01565642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goals of care decision support
Description: Decision aid and care plan meeting
Study NCT00263770 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: soft palate implant
Study NCT00836901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid
Description: 400 mg-57 mg chewable tablet
Study NCT00836901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin®
Description: 400 mg-57 mg chewable tablet
Study NCT00263770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft palate implant
Study NCT00263770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positive airway pressure (PAP)
Description: which is air delivered by a mask worn over the nose during sleep
Study NCT03407950 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IPT+
Description: Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
Study NCT03407950 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
Study NCT01220583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01220583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy
Study NCT01220583 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo radiotherapy
Study NCT00666354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study NCT00666354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study NCT00666354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study NCT02196207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eloctate Prophylaxis
Description: Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
Study NCT02196207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab Prophylaxis
Description: Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
Study NCT02034448 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous Renal Replacement Therapy
Study NCT00613041 — intervention group
Intervention type: PROCEDURE
Intervention: CT Scan
Description: All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
Study NCT02128009 — intervention group
Intervention type: OTHER
Intervention: osteoporosis
Study NCT02889302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Description: 24 weeks
Study NCT04129021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution retinal imaging through adaptive optics
Description: The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
Study NCT04129021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution retinal imaging through holographic systems
Description: The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
Study NCT03942653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Goserelin Acetate, SQ, Q4W
Study NCT02889302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks
Study NCT03942653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, IV, Q3W
Study NCT00835042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
Description: 1 x 15/25 mg
Study NCT04536792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946
Description: AG-946, oral encapsulated coated-granules or tablets.
Study NCT00835042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UNIRETIC® 15/25 mg tablets
Description: 1 x 15/25 mg
Study NCT02088554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 400 aortic valve bioprosthesis
Study NCT03100461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I2
Description: A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.).
Study NCT03100461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I2
Description: A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.).
Study NCT03100461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Standard of care approach that will provide basic information on CRC screening.
Study NCT04536792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946 Matched Placebo
Description: AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
Study NCT04150497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART22
Description: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
Study NCT04150497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLLS52
Description: A monoclonal antibody that recognizes a CD52 antigen
Study NCT02196207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eloctate ITI plus Emicizumab
Description: Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
Study NCT02196207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate ITI
Description: Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
Study NCT02851940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation
Description: Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
Study NCT02851940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Infusion
Description: Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
Study NCT01162928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutriflex Omega special + Oxepa
Description: 3-chamber-bag combined with enteral nutrition
Study NCT01162928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutriflex Lipid special + Pulmocare
Description: 3-chamber-bag combined with enteral nutrition
Study NCT04064177 — intervention group
Intervention type: DEVICE
Intervention: NICAS cardiac output monitor
Description: Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
Study NCT03102112 — intervention group
Intervention type: OTHER
Intervention: MRI examination
Description: A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
Study NCT00675259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
Study NCT00675259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 IV on days 1, 8, and 15
Study NCT01189682 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tegaderm, Tegaderm HP, Tegaderm CHG
Description: dressings on catheters
Study NCT01189682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm, Tegaderm HP, Tegaderm CHG
Description: dressings on catheters
Study NCT00675259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/M2 IV
Study NCT00675259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
Study NCT00675259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
Study NCT04205253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
Study NCT06637046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures
Description: A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
Study NCT06637046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
Study NCT02229331 — intervention group
Intervention type: OTHER
Intervention: Gait analysis
Study NCT06644677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV integration
Description: Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
Study NCT00851344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (10mg)
Description: GSK835726 (10mg) tablet
Study NCT00607477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: 2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week